Wegovy, a semaglutide remedy, will likely be lined by Medicare.
George Frey/Bloomberg through Getty Photographs
cover caption
toggle caption
George Frey/Bloomberg through Getty Photographs
Wegovy, a semaglutide remedy, will likely be lined by Medicare.
George Frey/Bloomberg through Getty Photographs
For the primary time, Medicare will permit protection of one of many new blockbuster weight-loss medicine for enrollees in Half D plans.
The plans could now cowl Wegovy when prescribed to forestall coronary heart assaults and strokes, in keeping with a brand new coverage issued this week from the Facilities for Medicare and Medicaid Providers.
Wegovy is a GLP-1 agonist, a category of weight problems medicine promising a sea change in weight reduction. They act on hormones and the mind to drastically cut back urge for food, amongst different issues.
However Medicare is prohibited from paying for weight-loss therapies so seniors have needed to pay out of pocket for the medicine or use supplemental insurance coverage. In early March, the Meals and Drug Administration expanded the approval of Wegovy to say the drug can be utilized to cut back the danger of cardiovascular dying, coronary heart assault and stroke in individuals with heart problems and both obese or weight problems.
In medical trials, Wegovy was discovered to cut back dangers of cardiovascular occasions by 20% in increased weight sufferers.
That discovering prompted CMS to vary its Medicare Half D drug program to cowl Wegovy, though it famous that this is applicable just for these sufferers scuffling with each weight and coronary heart illness. In different phrases, the injections, which might value nicely over $1,000 a month out of pocket, won’t be lined for enrollees solely looking for to reduce weight.
The brand new steerage additionally applies to state Medicaid plans, which additionally could be required to cowl Wegovy for sufferers with each increased weight and coronary heart illness threat.
Weight problems physician Angela Fitch says that the transfer to cowl it even for a restricted subset of sufferers remains to be vital. She’s president of the Weight problems Drugs Affiliation, a gaggle that advocates for therapy.
“It is definitely a giant step ahead, in comparison with no protection in any respect,” she says. “At the least now we’ll have protection for these individuals who have a recognized historical past of coronary heart illness,” she says. “So hopefully that can trickle down into overlaying it for everyone with obese and weight problems.”
And, Fitch notes, Medicare units the usual for protection in insurance coverage typically, so this transfer may finally have an effect on extra sufferers. “My hope could be that industrial insurance coverage would observe.”
In a press release, a CMS spokesperson mentioned: “CMS is dedicated to making sure that folks have entry to therapies and therapy choices that enhance well being outcomes.”
The Medicare steerage may additionally develop the usage of different related medicines. It states that anti-obesity drugs that obtain FDA approval for an extra situation apart from weight-management alone, may be thought of a Half D drug for that particular use. For instance, if one of many medicine receives FDA approval to deal with diabetes or stop heart problems, Medicare half D plans could cowl it for that use.
Nevertheless CMS specified they could additionally require prior authorizations to make sure that is getting used just for the accepted use.
In a press release, Wegovy’s maker Novo Nordisk mentioned it was “inspired” by the brand new steerage from CMS however mentioned it hopes to see Half D protection expanded for “weight problems medicines when used for persistent weight administration.”
The drug maker is amongst these pushing for Congress to develop protection of therapies for weight problems.
